Under construction – not a live service
Sign in
Taking people in PolandNo phase

Compares two surgeries to lower ovarian cancer risk in high-risk women

Tests removing the fallopian tubes first, with later ovary removal, in women with gene changes.

Key facts

Who runs it
University Medical Center Nijmegen
Where
Gdynia, Katowice, and Warsaw, PolandSee the 4 sitesAlso in 15 other countries, 62 sites
Trial code
Registry title
TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
Status
Recruiting
People taking part
3,000 people, planned
Started
1 Mar 2020
Expected to end
17 Feb 2040
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Risk-reducing salpingectomy with delayed oophorectomy
  • Risk-reducing salpingo-oophorectomy
Record updated
6 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women who carry a harmful BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 gene change and have finished having children. It compares removing the fallopian tubes first and the ovaries later with removing both at once.

Age
BRCA1: 25-40 years. BRCA2: 25-45 years. RAD51C, RAD51D, BRIP1: 25-50 years.
Sex
Women only.
Disease stage
No ovarian, fallopian tube or peritoneal cancer. A past cancer outside the ovaries is allowed. At least one fallopian tube must be present.
Earlier treatment
Cannot have had both fallopian tubes removed before.
Biomarker or test result
A class 5 (definitely pathogenic) germline mutation in BRCA1, BRCA2, RAD51C, RAD51D or BRIP1.

Main reasons for not taking part

  • Postmenopausal (natural or due to treatment)
  • Wish for the second surgery (ovary removal) within two years after the first
  • Past ovarian, fallopian tube or peritoneal cancer
  • Current diagnosis or treatment for cancer
  • Legally incapable

The registry criteria, word for word

Show all 12 criteriaShow less

Who can take part

  • Women with a class 5 (definitely pathogenic) BRCA1, BRCA2, RAD51C, RAD51D or BRIP1 germline mutation in one of the participating centers
  • Age at inclusion; BRCA1: 25-40 years; BRCA2: 25-45 years; RAD51C, RAD51D, BRIP1: 25-50 years
  • Childbearing completed
  • Presence of at least one fallopian tube
  • Participants may have a personal history of non-ovarian malignancy
  • Informed consent must be obtained and documented according to national and local regulatory requirements and the local rules followed in the institution

Who cannot take part

  • Prior bilateral salpingectomy
  • A personal history of ovarian, fallopian tube or peritoneal cancer
  • Current diagnosis or treatment for malignant disease
  • Postmenopausal status (natural menopause or due to treatment)
  • Wish for second stage RRO within two years after RRS
  • Legally incapable

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 25 and 50 years old?
  • Have you ever been told you have ovarian, fallopian tube or peritoneal cancer?

Where in Poland

Also in 15 other countries, 62 sites

  • Gdynia Oncology CentreGdynia, PolandContact: Maciej StukanTaking people
  • Bonifraterskie Centrum MedyczneKatowice, PolandContact: Monika Bodjys-SzyndlarTaking people
  • Medical University of SilesiaKatowice, PolandContact: Krzysztof NowosielskiTaking people
  • National Cancer Institute WarsawWarsaw, PolandContact: Agnieszka RychlikTaking people

About the trial

What the trial wants to find out

The aim of the project is to evaluate the risk-reducing salpingectomy with delayed oophorectomy as an alternative for risk-reducing salpingo-oophorectomy in high risk women with respect to ovarian cancer incidence.

The 2 groups in the trial

  • Risk-reducing salpingectomy with delayed oophorectomyTreatment being tested

    Risk-reducing salpingectomy after the completion of childbearing with delayed oophorectomy.

  • Risk-reducing salpingo-oophorectomyExisting treatment, for comparison

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
TUBectomy With Delayed Oophorectomy as Alternative for Risk-reducing Salpingo-oophorectomy in High Risk Women to Assess the Safety of Prevention: TUBA-WISP II Study.
Plain-language title
Compares two surgeries to lower ovarian cancer risk in high-risk womenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Fit questions
Built from NCT04294927, who can take part
Record updated
6 April 2026